Increasing Haemodialytic Clearances as Residual Renal Function Declines: An Incremental Approach

Blood Purification

Volumn 44, Issue 3, 2017, Pages 217-226

  Tangvoraphonkchai, Kamonwan ^a   Davenport, Andrew ^b  

^a MAHASARAKHAM UNIVERSITY   (Thailand)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; HEART VENTRICLE HYPERTROPHY; HEMODIALYSIS; HOSPITALIZATION; HUMAN; HYPOTENSION; INFLAMMATION; KIDNEY FUNCTION; NEUROPATHY; NUTRITIONAL STATUS; PRIORITY JOURNAL; QUALITY OF LIFE; RESIDUAL RENAL FUNCTION; REVIEW; TREATMENT OUTCOME; BLOOD; CHRONIC KIDNEY FAILURE; KIDNEY; METABOLISM; PATHOPHYSIOLOGY; SURVIVAL RATE; TIME FACTOR;

UREA;

HUMANS; KIDNEY; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SURVIVAL RATE; TIME FACTORS; UREA;

EID: 85027703930     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000475458     Document Type: Review

References (84)

1. Robinson BM, Akizawa T, Jager KJ, Kerr PG, Saran R, Pisoni RL: Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: Differences in access to renal replacement therapy, modality use, and haemodialysis practices. Lancet 2016; 388: 294-306.
2. Gotch FA, Sargent JA: A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 1985; 28: 526-534.
3. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019.
4. Meyer TW, Sirich TL, Fong KD, Plummer NS, Shafi T, Hwang S, et al: Kt/Vurea and nonurea small solute levels in the hemodialysis study. J Am Soc Nephrol 2016; 27: 3469-3478.
5. Lowrie EG, Laird NM, Parker TF, Sargent JA: Effect of the hemodialysis prescription of patient morbidity: Report from the National Cooperative Dialysis Study. N Engl J Med 1981; 305: 1176-1181.
6. Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, et al: Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009; 20: 645-654.
7. Peters SA, Bots ML, Canaud B, Davenport A, Grooteman MP, Kircelli F, et al: Haemodiafiltration and mortality in end-stage kidney disease patients: A pooled individual participant data analysis from four randomized controlled trials. Nephrol Dial Transplant 2016; 31: 978-984.
8. Farrington K, Davenport A: Would prescribing target Kt dose adjusted for body surface area improve hemodialysis outcomes? Kidney Int 2016; 90: 1160-1162.
9. Sirich TL, Meyer TW, Gondouin B, Brunet P, Niwa T: Protein-bound molecules: A large family with a bad character. Semin Nephrol 2014; 34: 106-117.
10. Obi Y, Streja E, Rhee CM, Ravel V, Amin AN, Cupisti A, et al: Incremental hemodialysis, residual kidney function, and mortality risk in incident dialysis patients: A cohort study. Am J Kidney Dis 2016; 68: 256-265.
11. Scribner BH, Cole JJ, Ahmad S, Blagg CR: Why thrice weekly dialysis? Hemodial Int 2004; 8: 188-192.
12. Davenport A, Hussain Sayed R, Fan S: The effect of racial origin on total body water volume in peritoneal dialysis patients. Clin J Am Soc Nephrol 2011; 6: 2492-2498.
13. Sridharan S, Vilar E, Davenport A, Ashman N, Almond M, Banerjee A, et al: Scaling hemodialysis target dose to reflect body surface area, metabolic activity, and protein catabolic rate: A prospective, cross-sectional study. Am J Kidney Dis 2017; 69: 358-366.
14. Merkus MP, Jager KJ, Dekker FW, de Haan RJ, Boeschoten EW, Krediet RT: Predictors of poor outcome in chronic dialysis patients: The Netherlands cooperative study on the adequacy of dialysis. The NECOSAD study group. Am J Kidney Dis 2000; 35: 69-79.
15. Wang AY, Wang M, Woo J, Law MC, Chow KM, Li PK, et al: A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int 2002; 62: 639-647.
16. Roumelioti ME, Nolin T, Unruh ML, Argyropoulos C: Revisiting the middle molecule hypothesis of uremic toxicity: A systematic review of beta 2 microglobulin population kinetics and large scale modeling of hemodialysis trials in silico. PLoS One 2016; 11:e0153157.
17. Sirich TL, Fong K, Larive B, Beck GJ, Chertow GM, Levin NW, et al: Limited reduction in uremic solute concentrations with increased dialysis frequency and time in the frequent hemodialysis network daily trial. Kidney Int 2017;pii:S0085-2538(16)30648-2.
18. Maduell F, Moreso F, Pons M, Ramos R, Mora-Macia J, Carreras J, et al: High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 2013; 24: 487-497.
19. Kandouz S, Mohamed AS, Zheng Y, Sandeman S, Davenport A: Reduced protein bound uraemic toxins in vegetarian kidney failure patients treated by haemodiafiltration. Hemodial Int 2016; 20: 610-617.
20. Daugirdas JT, Greene T, Rocco MV, Kaysen GA, Depner TA, Levin NW, et al: Effect of frequent hemodialysis on residual kidney function. Kidney Int 2013; 83: 949-958.
21. Lin YF, Huang JW, Wu MS, Chu TS, Lin SL, Chen YM, et al: Comparison of residual renal function in patients undergoing twice-weekly versus three-times-weekly haemodialysis. Nephrology (Carlton) 2009; 14: 59-64.
22. Zhang M, Wang M, Li H, Yu P, Yuan L, Hao C, et al: Association of initial twice-weekly hemodialysis treatment with preservation of residual kidney function in ESRD patients. Am J Nephrol 2014; 40: 140-150.
23. Grantham JJ, Wallace DP: Return of the secretory kidney. Am J Physiol Renal Physiol 2002; 282:F1-F9.
24. Suri RS, Larive B, Sherer S, Eggers P, Gassman J, James SH, et al: Risk of vascular access complications with frequent hemodialysis. J Am Soc Nephrol 2013; 24: 498-505.
25. Lee T, Roy-Chaudhury P: Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis. Adv Chronic Kidney Dis 2009; 16: 329-338.
26. Jun M, Jardine MJ, Gray N, Masterson R, Kerr PG, Agar JW, et al: Outcomes of extendedhours hemodialysis performed predominantly at home. Am J Kidney Dis 2013; 61: 247-253.
27. Herbelin A, Urena P, Nguyen AT, Zingraff J, Descamps-Latscha B: Influence of first and long-term dialysis on uraemia-associated increased basal production of interleukin-1 and tumour necrosis factor alpha by circulating monocytes. Nephrol Dial Transplant 1991; 6: 349-357.
28. Herbelin A, Urena P, Nguyen AT, Zingraff J, Descamps-Latscha B: Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991; 39: 954-960.
29. Donati D, Degiannis D, Raskova J, Raska K Jr: Uremic serum effects on peripheral blood mononuclear cell and purified T lymphocyte responses. Kidney Int 1992; 42: 681-689.
30. Stachowski J, Pollok M, Burrichter H, Spithaler C, Baldamus CA: Signalling via the TCR/CD3 antigen receptor complex in uremia is limited by the receptors number. Nephron 1993; 64: 369-375.
31. Nissenson AR, Fine RN: Clinical Dialysis, ed 4. New York, McGraw-Hill Medical Publishing Division, 2005, pp xviii, 1169.
32. Weinhandl ED, Liu J, Gilbertson DT, Arneson TJ, Collins AJ: Survival in daily home hemodialysis and matched thrice-weekly incenter hemodialysis patients. J Am Soc Nephrol 2012; 23: 895-904.
33. Daugirdas JT, Chertow GM, Larive B, Pierratos A, Greene T, Ayus JC, et al: Effects of frequent hemodialysis on measures of CKD mineral and bone disorder. J Am Soc Nephrol 2012; 23: 727-738.
34. Poulsen CG, Kjaergaard KD, Peters CD, Jespersen B, Jensen JD: Quality of life development during initial hemodialysis therapy and association with loss of residual renal function. Hemodial Int 2016, Epub ahead of print.
35. Shafi T, Jaar BG, Plantinga LC, Fink NE, Sadler JH, Parekh RS, et al: Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: The choices for healthy outcomes in caring for end-stage renal disease (CHOICE) study. Am J Kidney Dis 2010; 56: 348-358.
36. Park JI, Park JT, Kim YL, Kang SW, Yang CW, Kim NH, et al: Comparison of outcomes between the incremental and thrice-weekly initiation of hemodialysis: A propensitymatched study of a prospective cohort in Korea. Nephrol Dial Transplant 2017; 32: 355-363.
37. Arneson TJ, Liu J, Qiu Y, Gilbertson DT, Foley RN, Collins AJ: Hospital treatment for fluid overload in the Medicare hemodialysis population. Clin J Am Soc Nephrol 2010; 5: 1054-1063.
38. Davenport A, Sayed RH, Fan S: Is extracellular volume expansion of peritoneal dialysis patients associated with greater urine output? Blood Purif 2011; 32: 226-231.
39. Caria S, Cupisti A, Sau G, Bolasco P: The incremental treatment of ESRD: A low-protein diet combined with weekly hemodialysis may be beneficial for selected patients. BMC Nephrol 2014; 15: 172.
40. El-Kateb S, Sridharan S, Farrington K, Fan S, Davenport A: A single weekly Kt/Vurea target for peritoneal dialysis patients does not provide an equal dialysis dose for all. Kidney Int 2016; 90: 1342-1347.
41. Bolasco P, Cupisti A, Locatelli F, Caria S, Kalantar-Zadeh K: Dietary management of incremental transition to dialysis therapy: Onceweekly hemodialysis combined with low-protein diet. J Ren Nutr 2016; 26: 352-359.
42. Shafi T, Michels WM, Levey AS, Inker LA, Dekker FW, Krediet RT, et al: Estimating residual kidney function in dialysis patients without urine collection. Kidney Int 2016; 89: 1099-1110.
43. Wong J, Sridharan S, Berdeprado J, Vilar E, Viljoen A, Wellsted D, et al: Predicting residual kidney function in hemodialysis patients using serum beta-trace protein and beta2-microglobulin. Kidney Int 2016; 89: 1090-1098.
44. Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT, et al: Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002; 62: 1046-1053.
45. Verde E, Perez de Prado A, Lopez-Gomez JM, Quiroga B, Goicoechea M, Garcia-Prieto A, et al: Asymptomatic intradialytic supraventricular arrhythmias and adverse outcomes in patients on hemodialysis. Clin J Am Soc Nephrol 2016; 11: 2210-2217.
46. Fujii H, Kim JI, Yoshiya K, Nishi S, Fukagawa M: Clinical characteristics and cardiovascular outcomes of hemodialysis patients with atrial fibrillation: A prospective follow-up study. Am J Nephrol 2011; 34: 126-134.
47. Rayner HC, Zepel L, Fuller DS, Morgenstern H, Karaboyas A, Culleton BF, et al: Recovery time, quality of life, and mortality in hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2014; 64: 86-94.
48. Flythe JE, Curhan GC, Brunelli SM: Shorter length dialysis sessions are associated with increased mortality, independent of body weight. Kidney Int 2013; 83: 104-113.
49. Asano M, Thumma J, Oguchi K, Pisoni RL, Akizawa T, Akiba T, et al: Vascular access care and treatment practices associated with outcomes of arteriovenous fistula: International comparisons from the Dialysis Outcomes and Practice Patterns Study. Nephron Clin Pract 2013; 124: 23-30.
50. Wang AY, Lai KN: The importance of residual renal function in dialysis patients. Kidney Int 2006; 69: 1726-1732.
51. Fotheringham J, Fogarty DG, El Nahas M, Campbell MJ, Farrington K: The mortality and hospitalization rates associated with the long interdialytic gap in thrice-weekly hemodialysis patients. Kidney Int 2015; 88: 569-575.
52. McCafferty K, Fan S, Davenport A: Extracellular volume expansion, measured by multifrequency bioimpedance, does not help preserve residual renal function in peritoneal dialysis patients. Kidney Int 2014; 85: 151-157.
53. Rhee H, Baek MJ, Chung HC, Park JM, Jung WJ, Park SM, et al: Extracellular volume expansion and the preservation of residual renal function in Korean peritoneal dialysis patients: A long-term follow up study. Clin Exp Nephrol 2016; 20: 778-786.
54. Mustafa RA, Bdair F, Akl EA, Garg AX, Thiessen-Philbrook H, Salameh H, et al: Effect of lowering the dialysate temperature in chronic hemodialysis: A systematic review and metaanalysis. Clin J Am Soc Nephrol 2016; 11: 442-457.
55. Dunne N: A meta-analysis of sodium profiling techniques and the impact on intradialytic hypotension. Hemodial Int 2016, Epub ahead of print.
56. Zhou YL, Liu HL, Duan XF, Yao Y, Sun Y, Liu Q: Impact of sodium and ultrafiltration profiling on haemodialysis-related hypotension. Nephrol Dial Transplant 2006; 21: 3231-3237.
57. Donauer J, Schweiger C, Rumberger B, Krumme B, Bohler J: Reduction of hypotensive side effects during online-haemodiafiltration and low temperature haemodialysis. Nephrol Dial Transplant 2003; 18: 1616-1622.
58. Hyodo T, Koutoku N: Preservation of residual renal function with HDF. Contrib Nephrol 2011; 168: 204-212.
59. Pizzarelli F, Cerrai T, Dattolo P, Ferro G: On-line haemodiafiltration with and without acetate. Nephrol Dial Transplant 2006; 21: 1648-1651.
60. Tessitore N, Santoro A, Panzetta GO, Wizemann V, Perez-Garcia R, Martinez Ara J, et al: Acetate-free biofiltration reduces intradialytic hypotension: A European multicenter randomized controlled trial. Blood Purif 2012; 34: 354-363.
61. Ding F, Ahrenholz P, Winkler RE, Ramlow W, Tiess M, Michelsen A, et al: Online hemodiafiltration versus acetate-free biofiltration: A prospective crossover study. Artif Organs 2002; 26: 169-180.
62. Fagugli RM, Pasini P, Quintaliani G, Pasticci F, Ciao G, Cicconi B, et al: Association between extracellular water, left ventricular mass and hypertension in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 2332-2338.
63. Fissell WH, Roy S, Davenport A: Achieving more frequent and longer dialysis for the majority: Wearable dialysis and implantable artificial kidney devices. Kidney Int 2013; 84: 256-264.
64. Basile C, Libutti P, Di Turo AL, Casino FG, Vernaglione L, Tundo S, et al: Removal of uraemic retention solutes in standard bicarbonate haemodialysis and long-hour slowflow bicarbonate haemodialysis. Nephrol Dial Transplant 2011; 26: 1296-1303.
65. Eloot S, Van Biesen W, Dhondt A, Van de Wynkele H, Glorieux G, Verdonck P, et al: Impact of hemodialysis duration on the removal of uremic retention solutes. Kidney Int 2008; 73: 765-770.
66. Raj DS, Ouwendyk M, Francoeur R, Pierratos A: Beta(2)-microglobulin kinetics in nocturnal haemodialysis. Nephrol Dial Transplant 2000; 15: 58-64.
67. Leypoldt JK, Cheung AK, Deeter RB: Rebound kinetics of beta2-microglobulin after hemodialysis. Kidney Int 1999; 56: 1571-1577.
68. Leypoldt JK, Meijers BK: Effect of treatment duration and frequency on uremic solute kinetics, clearances and concentrations. Semin Dial 2016; 29: 463-470.
69. Lornoy W, Becaus I, Billiouw JM, Sierens L, van Malderen P: Remarkable removal of beta-2-microglobulin by on-line hemodiafiltration. Am J Nephrol 1998; 18: 105-108.
70. Maduell F, Navarro V, Cruz MC, Torregrosa E, Garcia D, Simon V, et al: Osteocalcin and myoglobin removal in on-line hemodiafiltration versus low-A nd high-flux hemodialysis. Am J Kidney Dis 2002; 40: 582-589.
71. Ward RA, Schmidt B, Hullin J, Hillebrand GF, Samtleben W: A comparison of on-line hemodiafiltration and high-flux hemodialysis: A prospective clinical study. J Am Soc Nephrol 2000; 11: 2344-2350.
72. Meert N, Eloot S, Waterloos MA, Van Landschoot M, Dhondt A, Glorieux G, et al: Effective removal of protein-bound uraemic solutes by different convective strategies: A prospective trial. Nephrol Dial Transplant 2009; 24: 562-570.
73. Canaud B, Barbieri C, Marcelli D, Bellocchio F, Bowry S, Mari F, et al: Optimal convection volume for improving patient outcomes in an international incident dialysis cohort treated with online hemodiafiltration. Kidney Int 2015; 88: 1108-1116.
74. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y: Removal of the protein-bound solute p-cresol by convective transport: A randomized crossover study. Am J Kidney Dis 2004; 44: 278-285.
75. Sirich TL, Luo FJ, Plummer NS, Hostetter TH, Meyer TW: Selectively increasing the clearance of protein-bound uremic solutes. Nephrol Dial Transplant 2012; 27: 1574-1579.
76. Heyne N, Guthoff M, Krieger J, Haap M, Haring HU: High cut-off renal replacement therapy for removal of myoglobin in severe rhabdomyolysis and acute kidney injury: A case series. Nephron Clin Pract 2012; 121:c159-c164.
77. Kirsch AH, Lyko R, Nilsson LG, Beck W, Amdahl M, Lechner P, et al: Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transplant 2017; 32: 165-172.
78. Villa G, Zaragoza JJ, Sharma A, Neri M, De Gaudio AR, Ronco C: Cytokine removal with high cut-off membrane: Review of literature. Blood Purif 2014; 38: 167-173.
79. Galli F, Benedetti S, Buoncristiani U, Piroddi M, Conte C, Canestrari F, et al: The effect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels. Kidney Int 2003; 64: 748-755.
80. Tijink MS, Wester M, Glorieux G, Gerritsen KG, Sun J, Swart PC, et al: Mixed matrix hollow fiber membranes for removal of proteinbound toxins from human plasma. Biomaterials 2013; 34: 7819-7828.
81. Kruse A, Tao X, Bhalani V, Handelman G, Levin NW, Kotanko P, et al: Clearance of pcresol sulfate and ?-2-microglobulin from dialysate by commercially available sorbent technology. ASAIO J 2011; 57: 219-224.
82. Meyer TW, Peattie JW, Miller JD, Dinh DC, Recht NS, Walther JL, et al: Increasing the clearance of protein-bound solutes by addition of a sorbent to the dialysate. J Am Soc Nephrol 2007; 18: 868-874.
83. Krieter DH, Devine E, Korner T, Ruth M, Wanner C, Raine M, et al: Haemodiafiltration at increased plasma ionic strength for improved protein-bound toxin removal. Acta Physiol (Oxf) 2017; 219: 510-520.
84. Tao X, Thijssen S, Kotanko P, Ho CH, Henrie M, Stroup E, et al: Improved dialytic removal of protein-bound uraemic toxins with use of albumin binding competitors: An in vitro human whole blood study. Sci Rep 2016; 6: 23389.